Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection.

Journal of viral hepatitis - 1 Aug 2012

Girardin F, Daali Y, Gex-Fabry M, Rebsamen M, Roux-Lombard P, Cerny A, Bihl F, Binek J, Moradpour D, Negro F, Desmeules J

Abstract excerpt

Liver kidney microsomal type 1 (LKM-1) antibodies have been shown to decrease the CYP2D6 activity in vitro and are present in a minority of patients with chronic hepatitis C infection. We investigated whether LKM-1 antibodies might reduce the CYP2D6 activity in vivo. All patients enrolled in the Swiss Hepatitis C Cohort Study and tested for LKM-1 antibodies were assessed (n = 1723): 10 eligible patients were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Autoantibodies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Cytochrome P-450 CYP2D6

Share to Dextromethorphan

Share to Genotype

Share to Hepatitis C, Chronic

Share to Switzerland

Source

Identifiers

PMID: 22762141
DOI: 10.1111/j.1365-2893.2011.01578.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection.PMID 22762141Read ↗

Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.Semantic proximity Read ↗

[Diagnosis of hepatic enzyme activities of drug metabolizing enzymes-phenotyping and genotyping].Semantic proximity Read ↗

Interferon therapy in LKM-1 positive patients with chronic hepatitis C: follow-up by a quantitative radioligand assay for CYP2D6 antibody detection.Semantic proximity Read ↗

Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate.Semantic proximity Read ↗

Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser.Semantic proximity Read ↗

CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype.Semantic proximity Read ↗

Impairment of metabolic function in chronic hepatitis C is related to factors associated with resistance to therapy.Semantic proximity Read ↗

Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.Semantic proximity Read ↗

In Vivo Functional Effects of CYP2C9 M1L, a Novel and Common Variant in the Yup'ik Alaska Native Population.Semantic proximity Read ↗

Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.Semantic proximity Read ↗

Is debrisoquine hydroxylation modified during acute viral hepatitis?Semantic proximity Read ↗

CYP2D6 polymorphism and the presence of anti-LKM-1 in patients with chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.